V deos calientes

Hot Ones

2016.08.05 01:44 n_that Hot Ones

The Show with Hot Questions and Even Hotter Wings
[link]

2024.06.05 20:24 ZevrPL Maszyna do zaspokajania nagłych potrzeb - bez skojarzeń proszę.

Maszyna do zaspokajania nagłych potrzeb - bez skojarzeń proszę.
Siema
Dziwny temat, ale odnosi się do maszyny którą znalazłem w świecie gry.
Stoi sobie kilka maszyn z czego w jednej leży plik kasy, po zabraniu z maszyny wypada kolejny i tak 6 razy. Po szóstym razie, zostajemy porażeni prądem. Tak jak widać na zdjęciu nie można nic zrobić. Po podejściu bliżej też nic nie możemy zrobić. Szukałem informacji w internecie o tym, ale niestety nic nie znalazłem. Może ktoś z Was rozwiąże "tą zagadkę"?
https://preview.redd.it/dl17qbe5ps4d1.png?width=1920&format=png&auto=webp&s=ad20ef5690122808ac6357c63c39fd294ccd3035
Lokalizacja:
https://preview.redd.it/7fnusbw8ps4d1.png?width=1920&format=png&auto=webp&s=68a159609cfcf0f531a1b769d2c3cb5950fdc65e
submitted by ZevrPL to cyberpunkgame [link] [comments]

2024.06.05 18:09 MightBeneficial3302 NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
​
https://preview.redd.it/ssj9aa2x1s4d1.png?width=300&format=png&auto=webp&s=65a900abd2aa90a39d2a8aacfaa0facfaa3a917d
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release. The Company’s full set of consolidated financial statements for the three months ended March 31, 2024, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca.
Key Business Highlights
On March 1, 2024, the Company commenced the setup of in-house laboratories and offices to bolster its research and development capabilities, subsequent to entering into lease and construction agreements. Completion of these initiatives is anticipated by the end of June 2024.
On March 22, 2024, the Company completed the acceleration of 12,682,340 warrants issued pursuant to a private placement of units that closed on June 15, 2022. Following the acceleration event, the Company received gross proceeds of US$2.92 million (approximately C$4.0 million) from the exercise of 10,423,629 common share purchase warrants, which represented accelerated and non-accelerated warrants of which 9,684,993 warrants were exercised at a price of C$0.38, 556,818 warrants were exercised at a price of C$0.34, and 181,818 warrants were exercised at a price of C$0.48. The Company exercised its right to accelerate the expiry date of certain warrants to thirty days upon the Company’s common shares exceeded C$0.475 for ten consecutive trading days on the TSX Venture Exchange (“TSXV”). “We appreciate the confidence of the investors who exercise their warrants, and the ongoing support of NurExone’s journey,” stated Eran Ovadya, NurExone Chief Financial Officer.
On April 1, 2024, the Company entered into a Contract Research Organization services agreement with Vivox Ltd. for animal experiments as part of the preclinical testing phase for the submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (the “FDA”). This is aimed at assessing the safety and efficacy of the ExoPTEN drug before proceeding to clinical trials involving human subjects, which are anticipated to commence in 2025. This engagement followed the completion of a Pre-IND meeting with the FDA regarding the manufacturing, preclinical, and clinical development plan of ExoPTEN, NurExone’s inaugural ExoTherapy product, and the subsequent receipt of a written response from the FDA.
On April 25, 2024, NurExone successfully secured approval for listing on the OTCQB Venture Market, marking a significant milestone in the Company's growth and visibility within the financial community, including in the USA. In addition, the Company achieved Depository Trust Company eligibility, which enhances the efficiency and cost-effectiveness of trading NurExone shares, facilitating better liquidity and broader access for investors.
Growth Outlook for 2024
According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is committed to pioneering transformations in the field of regenerative medicine with new, minimally invasive therapies and we are moving along the regulatory path towards human trials for our first product, ExoPTEN. Our focus remains on enhancing our ExoTherapy platform for the production of nanodrugs, expanding our intellectual property, and forging strategic collaborations. Towards this end, we have recently engaged Dr. Ram Petter, Vice President and head of Bio Strategy at Teva Pharmaceutical, to support our efforts in collaborating with biopharma companies.”
First Quarter Fiscal 2024 Financial Results
  • Research and development expenses were US$0.22 million in the first quarter of 2024, compared to US$0.37 million in the same quarter in 2023. The decrease was primarily due to the receipt of a governmental grant of US$0.02 and reductions in stock-based compensation of US$0.08, subcontractor and materials expenses of US$0.05.
  • General and administrative expenses were US$0.70 million in the first quarter of 2024, compared to US$0.35 million in the same period in 2023. The increase was primarily due to costs related to public and investor relations services.
  • Finance expenses were US$0.01 million in the first quarter of 2024, compared to finance income of US$0.01 million in the same period in 2023, driven by income from bank interest.
  • Net loss was US$0.92 million in the first quarter of 2024, compared to a net loss of US$0.70 million in the first quarter of 2023.
As of March 31, 2024, the Company had cash and cash equivalents of US$3.25 million (December 31, 2023 - US$0.54 million) and working capital of US$3.31 million (December 31, 2023 - US$0.07 million). The increase in cash was primarily due to the completion of a private placement in January 2024 for gross proceeds of approximately US$1.49 million and the exercise of warrants in March 2024 for gross proceeds of approximately US$2.92 million.
The Company had an accumulated deficit of US$14.98 million as of March 31, 2024, (December 31, 2023 - US$14.06 million).
Eran Ovadya, NurExone’s Chief Financial Officer, added: “The Company maintains a strong cash position, ensuring sufficient funding until year-end. With strategic oversight, we navigate our business plan amidst ongoing activities, positioning ourselves for sustained growth and continued success.”
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com
Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com
Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu
submitted by MightBeneficial3302 to Wealthsimple_Penny [link] [comments]

2024.06.05 18:09 MightBeneficial3302 NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
​
https://preview.redd.it/skjldluv1s4d1.png?width=300&format=png&auto=webp&s=703ab35b18988abdd8254bc99f308cc1ad824f32
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release. The Company’s full set of consolidated financial statements for the three months ended March 31, 2024, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca.
Key Business Highlights
On March 1, 2024, the Company commenced the setup of in-house laboratories and offices to bolster its research and development capabilities, subsequent to entering into lease and construction agreements. Completion of these initiatives is anticipated by the end of June 2024.
On March 22, 2024, the Company completed the acceleration of 12,682,340 warrants issued pursuant to a private placement of units that closed on June 15, 2022. Following the acceleration event, the Company received gross proceeds of US$2.92 million (approximately C$4.0 million) from the exercise of 10,423,629 common share purchase warrants, which represented accelerated and non-accelerated warrants of which 9,684,993 warrants were exercised at a price of C$0.38, 556,818 warrants were exercised at a price of C$0.34, and 181,818 warrants were exercised at a price of C$0.48. The Company exercised its right to accelerate the expiry date of certain warrants to thirty days upon the Company’s common shares exceeded C$0.475 for ten consecutive trading days on the TSX Venture Exchange (“TSXV”). “We appreciate the confidence of the investors who exercise their warrants, and the ongoing support of NurExone’s journey,” stated Eran Ovadya, NurExone Chief Financial Officer.
On April 1, 2024, the Company entered into a Contract Research Organization services agreement with Vivox Ltd. for animal experiments as part of the preclinical testing phase for the submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (the “FDA”). This is aimed at assessing the safety and efficacy of the ExoPTEN drug before proceeding to clinical trials involving human subjects, which are anticipated to commence in 2025. This engagement followed the completion of a Pre-IND meeting with the FDA regarding the manufacturing, preclinical, and clinical development plan of ExoPTEN, NurExone’s inaugural ExoTherapy product, and the subsequent receipt of a written response from the FDA.
On April 25, 2024, NurExone successfully secured approval for listing on the OTCQB Venture Market, marking a significant milestone in the Company's growth and visibility within the financial community, including in the USA. In addition, the Company achieved Depository Trust Company eligibility, which enhances the efficiency and cost-effectiveness of trading NurExone shares, facilitating better liquidity and broader access for investors.
Growth Outlook for 2024
According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is committed to pioneering transformations in the field of regenerative medicine with new, minimally invasive therapies and we are moving along the regulatory path towards human trials for our first product, ExoPTEN. Our focus remains on enhancing our ExoTherapy platform for the production of nanodrugs, expanding our intellectual property, and forging strategic collaborations. Towards this end, we have recently engaged Dr. Ram Petter, Vice President and head of Bio Strategy at Teva Pharmaceutical, to support our efforts in collaborating with biopharma companies.”
First Quarter Fiscal 2024 Financial Results
  • Research and development expenses were US$0.22 million in the first quarter of 2024, compared to US$0.37 million in the same quarter in 2023. The decrease was primarily due to the receipt of a governmental grant of US$0.02 and reductions in stock-based compensation of US$0.08, subcontractor and materials expenses of US$0.05.
  • General and administrative expenses were US$0.70 million in the first quarter of 2024, compared to US$0.35 million in the same period in 2023. The increase was primarily due to costs related to public and investor relations services.
  • Finance expenses were US$0.01 million in the first quarter of 2024, compared to finance income of US$0.01 million in the same period in 2023, driven by income from bank interest.
  • Net loss was US$0.92 million in the first quarter of 2024, compared to a net loss of US$0.70 million in the first quarter of 2023.
As of March 31, 2024, the Company had cash and cash equivalents of US$3.25 million (December 31, 2023 - US$0.54 million) and working capital of US$3.31 million (December 31, 2023 - US$0.07 million). The increase in cash was primarily due to the completion of a private placement in January 2024 for gross proceeds of approximately US$1.49 million and the exercise of warrants in March 2024 for gross proceeds of approximately US$2.92 million.
The Company had an accumulated deficit of US$14.98 million as of March 31, 2024, (December 31, 2023 - US$14.06 million).
Eran Ovadya, NurExone’s Chief Financial Officer, added: “The Company maintains a strong cash position, ensuring sufficient funding until year-end. With strategic oversight, we navigate our business plan amidst ongoing activities, positioning ourselves for sustained growth and continued success.”
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com
Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com
Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu
submitted by MightBeneficial3302 to 10xPennyStocks [link] [comments]

2024.06.05 02:22 Confident_Thing_7386 Best Atari special controller

Best Atari special controller submitted by Confident_Thing_7386 to Atari2600 [link] [comments]

2024.06.04 20:38 Scyth-sh Tactical Ops: Friendly games 3.5, 03-06-2024

Tactical Ops: Friendly games 3.5, 03-06-2024 submitted by Scyth-sh to tacticalops [link] [comments]

2024.06.04 19:24 alexiskurien Part number of power port

I am a complete noob. Please help. My laptop is not charging. It seems the power port is jot working as the adaptor works with other laptop. I tried to find it using service tag but couldn't understand the jargon. Please see below
UK/EN Inspiron 7591 2-in-1 Log in to add alias Inspiron 7591 2-in-1 Service Tag: G0XVFW2
Express Service Code: 34885411634
Support Services: Expired 16 MAR 2021
Manage Services
Change product System Configuration
Original Configuration Detailed below is your device's (Service Tag: G0XVFW2) original configuration and the system specifications it shipped with.
Export Collapse All X101C : Module,Cord,Power,250V,1M,C5,U nited Kingdom Part Number
J663C
Description
CORD,PWR,250V,2.5A,1M,C5,UK
Quantity
1
WRXCJ : MOD,ASSY,BASE,I7-10510U,U,7591 Part Number
41FKY
Description
ASSY,BASE,NB,I7-10510U,U,7591
Quantity
1
Part Number
9P0HV
Description
ASSY,SPKR,2W,25X14X4.7MM,7590
Quantity
1
WN6C1 : MOD,SHP MTL,INSP,JEDI CML,15 Part Number
29W20
Description
SHP MTL,ACC,UPAD,INSP,15
Quantity
1
Part Number
3XRWR
Description
SHP MTL,BOX,SYSM,15,DRCT
Quantity
1
Part Number
4K6MC
Description
SHP MTL,CSHN,MPP,KYLOMLK,15
Quantity
2
Part Number
C402F
Description
SHP MTL,BAG,NBK,HDPE,2SD
Quantity
1
WJ8P2 : BASE,NBK,INSP,BTX,7591 Part Number
9872G
Description
LBL,SVC TAG/EXPRESS CODE,ANW
Quantity
1
Part Number
PG98R
Description
INFO,SWSI,NB,CVT,INSP,7591
Quantity
1
Part Number
PHJFR
Description
INFO,RYLTY,INSYDE,AGS,BIOS,NBK
Quantity
1
Part Number
XPRGW
Description
INFO,UEFI-CL3
Quantity
1
V33K7 : Module,Information,Direct Ship ,Wistron,CHENGDU Part Number
KW659
Description
INFO,DIRSHP,WSTN
Quantity
1
RN0NJ : MOD,SW,DPK,W10H,HE Part Number
5Y1G2
Description
DPK,W10H,PLUS
Quantity
1
PYC0K : MOD,SW,W10,EDITION,HOME Part Number
CDDD8
Description
INFO,WIN10,HOME
Quantity
1
PRF01 : Module,Plate,Software Support Diskette,Thermal,7590 Part Number
PHPM6
Description
PLT,SSD,THRM,7590
Quantity
1
P7HXK : MOD,LBL,REG,INSP,WW,7591 Part Number
8FP90
Description
LBL,REG,INSP,WW,7591
Quantity
1
P6XPR : Module,Software,CRRS,Multiple User Interface Part Number
C2N45
Description
INFO,SW,CRRS,UPDATE
Quantity
1
Part Number
YR2T2
Description
SRV,SW,CRRS,MUI
Quantity
1
P4V68 : MOD,SW,APP,SACLIENT Part Number
334CH
Description
SRV,SW,APP,SACLIENT
Quantity
1
Part Number
7CVVR
Description
SRV,SW,APP,SACLIENT,W10S
Quantity
1
Part Number
K53RM
Description
INFO,RYLTY,SACLIENT
Quantity
1
N4V2Y : Module,Software,Appian,NETFLIX Part Number
0C7WX
Description
SRV,SW,APP,NETFLIX
Quantity
1
Part Number
44C2D
Description
INFO,RYLTY,NETFLIX
Quantity
1
MX962 : Module,Information,NO MEDIA Part Number
864KE
Description
Information,PLACEHOLDER PIECE-PART
Quantity
1
MTYW0 : Module,Software,Office,Multipl e User Interface,Factory Insta ll Part Number
7M1KY
Description
SRV,SW,OFFICE,OPK
Quantity
1
Part Number
HR8X9
Description
INFO,WINRE-ADDR,3,GB-PTN
Quantity
1
MM4KC : MOD,SW,DMC,ROW Part Number
HJ69H
Description
INFO,RYLTY,SCREENOVATE,DMC,ROW
Quantity
1
Part Number
PMGWT
Description
SRV,SW,DMC
Quantity
1
M945V : MOD,LCD,15.6FHD,TS,LB,AUO,7590 Part Number
HXMYH
Description
INFO,SWSI,LCD,15.6,TCH
Quantity
1
Part Number
NPR9W
Description
ASSY,LCD,15.6FHD,TSP,LB,AUO
Quantity
1
KHCK5 : MOD,INFO,GNRC Part Number
W21JJ
Description
INFO,GNRC,OEM,TRACKING,PN
Quantity
1
JVW5F : MOD,CVR,LCD,SLVR,FHD,7591 Part Number
5XM8G
Description
KIT,CVR,LCD,FHD,SLVR,TCH,7591
Quantity
1
Part Number
9D4V0
Description
FPRDR,MODULE,SILVER,7591/5584
Quantity
1
Part Number
GVJ4P
Description
ASSY,PLMRST,SLVR,7591
Quantity
1
Part Number
HK46K
Description
ASSY,CMRA,HD,RGB,USB,2MIC,FF
Quantity
1
Part Number
KF10V
Description
ASSY,TPAD,W/BRKT,7590
Quantity
1
JJ8DK : MOD,SW,WIN10,64,ENGLISH,WW Part Number
0616F
Description
INFO,BOOT,GPT,OVERRIDE
Quantity
1
Part Number
D6KX0
Description
INFO,WINDOWS,10
Quantity
1
Part Number
HNX8N
Description
INFO,IE@V,110000
Quantity
1
Part Number
KYWGW
Description
INFO,.NET@V,46000
Quantity
1
Part Number
PJ289
Description
INFO,VPEPR
Quantity
1
Part Number
PY79K
Description
INFO,.NET@V,50000
Quantity
1
Part Number
T2673
Description
Service Charge,Operating System,Windows XP OCA-MARKER
Quantity
1
Part Number
TM318
Description
INFO,SLP2,ENABLE,WINDOWS
Quantity
1
Part Number
V4DPY
Description
SRV,OS,WIN10,64,ENG
Quantity
1
Part Number
W728F
Description
SRV,OS,IE,INSTALLER
Quantity
1
Part Number
X0601
Description
INFO,BYPS,UPTN
Quantity
1
Part Number
X278C
Description
SRV,OS,DOTNET,INSTALLER
Quantity
1
Part Number
XP9T9
Description
INFO,BOOT,CNTNR,GPT
Quantity
1
JJ7YH : MOD,CRD,NTWK,M2,9560AC,WW,CSMB Part Number
T0HRM
Description
CRD,WRLES,M.2,INTEL9560,WW
Quantity
1
Part Number
VP2R0
Description
LBL,REG,WRLES,9560AC,WW,CSMB
Quantity
1
J79YK : MOD,BTRY,51WHR,3C,LITH,BYD Part Number
TNT6H
Description
Battery,Primary,51WHR,3C,Lithium,BYD
Quantity
1
GMXR6 : Module,Information,Label,Print On Demand,Dell Energy Offerin g,Energy Star Part Number
51H8W
Description
INSTR,ODM,POD,LBL,DEO,ESTAR
Quantity
1
Part Number
9XP3W
Description
INFO,LBL,DEO,ESTAR
Quantity
1
G4F9T : MOD,SSDR,512G,P34,30S3,BG4 Part Number
2HMFM
Description
INFO,C DRIVE,PCIESSD
Quantity
1
Part Number
8C3CP
Description
SSDR,512G,P34,30S3,TOSHIBA,BG4
Quantity
1
DT8TF : MOD,BRKT,HDD,W/CBL,7590 Part Number
GY6JY
Description
ASSY,BRKT,HDD,7591
Quantity
1
CWF0W : Module,Software,DELL-UPDATE Part Number
15V18
Description
SRV,SW,DELL-UPDATE,UWP
Quantity
1
Part Number
83VMP
Description
INFO,.NET@V,47000
Quantity
1
C2WVP : Module,Adapter,Alternating Cur rent,65W,Liteon,3P,Pwa Integra ted,WW2 Part Number
MGJN9
Description
Adapter,Alternating Current,65W,Liteon,3P,Pwa Integrated,4.5MM
Quantity
1
9KC7Y : MOD,PLCMT,GETS,7591,SLVR,WW Part Number
VV2NW
Description
PLCMT,GETS,INSP,7591SILVER,WW
Quantity
1
9JMWH : MOD,KYBD,102,UK,M18NXR-UBSK Part Number
NH88W
Description
KYBD,102,UK,M18NXR-UBSK
Quantity
1
Part Number
R9T05
Description
INFO,KYBD,BLIT,XLOB
Quantity
1
9G58W : MOD,LBL,INTEL,CI7,10, SMALL Part Number
6K2WJ
Description
LBL,INTEL,CI7,10, SMALL
Quantity
1
97FD6 : MOD,LBL,BLNK,2.25X9.875,XPS13 Part Number
5GWJX
Description
LBL,POD,CFIG,2.2X9.8
Quantity
1
85Y47 : Module,Software,COMMONBUILD,Ac ross Line Of Business Part Number
4F6WW
Description
SRV,SW,MCAFEE,COMMONBUILD,M
Quantity
1
Part Number
FD09N
Description
SRV,SW,MCAFE,CB,LIVESAFE,WIN10
Quantity
1
Part Number
GVXWF
Description
INFO,SW,MCAFEE+,30DAY
Quantity
1
Part Number
M8192
Description
SRV,SW,MCAF-SCTY,UPDATES
Quantity
1
Part Number
V7CT5
Description
SRV,SW,MCAFEE,COMMONBUILD
Quantity
1
7FN80 : MOD,INFO,EMEA Part Number
06VKF
Description
INSTR,GNRC,EMEA
Quantity
1
5J7CF : Module,Software,Microsoft,Tran slator,W10 Part Number
PT0YN
Description
SRV,SW,MS,XLTR,W10
Quantity
1
4XMG3 : Module,Software,PULSE Part Number
7VDFT
Description
SRV,SW,OTB,SURV
Quantity
1
4267X : MOD,LBL,RTL,PLMRST,FHD,ENG,15 Part Number
R7NFJ
Description
LBL,RTL,PLMRST,FHD,ENG,7591
Quantity
1
40HKW : Module,Software,DROPBOX,Factor y Install Part Number
0K1F2
Description
SRV,SW,DROPBOX
Quantity
1
Part Number
29GT3
Description
INFO,RYLTY,DROPBOX,FI
Quantity
1
3KWGW : MOD,GDE,PROD,MUI,SERI,EMEA 2 Part Number
T1X53
Description
TSH,REG,EU,RED,WW
Quantity
1
Part Number
YWKX2
Description
GDE,PROD,MUI,SERI,EMEA 2
Quantity
1
22NYC : MOD-SRV,SW,9560,JEDI Part Number
FW87F
Description
SRV,APPS,BT,AX-9X6X,JEDI
Quantity
1
Part Number
M3P9G
Description
SRV,DRVR,WIFI,AX-9X6X,JEDI
Quantity
1
1RC54 : MOD,SW,PRRT-DIS,CIN-CLR Part Number
53KXY
Description
SRV,SW,PRRT-DIS,CIN-CLR
Quantity
1
Part Number
5DG85
Description
INFO,RYLTY,PRRT-DIS,CIN-CLR
Quantity
1
0WMJV : Module,Software,Appian,MY DELL Part Number
4H7K9
Description
SRV,SW,MY DELL
Quantity
1
0P1H1 : MOD,SW,QFE,WIN10 Part Number
0RR64
Description
SRV,SW,JUMPSTART,W10
Quantity
1
Part Number
D6KX0
Description
INFO,WINDOWS,10
Quantity
1
Part Number
GYTDF
Description
SRV,SW,WIN10,RDX
Quantity
1
Part Number
NGC17
Description
SRV,WINDOWS,REG,PWR
Quantity
1
Part Number
X7V4Y
Description
INFO,RYLTY,W10,DOLBY5.1,CODEC
Quantity
1
03N80 : MOD-SRV,SW,INSP,WIN,7591 Part Number
07HF9
Description
SRV,DRVR,ESTR,XLOB
Quantity
1
Part Number
0G81K
Description
SRV,DRVR,MEI,JEDI
Quantity
1
Part Number
0PHP8
Description
SRV,DRVR,SGX,JEDI
Quantity
1
Part Number
0WJWR
Description
SRV,SW,EXCAL-SOS/DDRE,BASE
Quantity
1
Part Number
1T9H3
Description
SRV,DRVR,SERIAL IO,JEDI
Quantity
1
Part Number
2FXVW
Description
SRV,DRVR,CHIPSET,JEDI
Quantity
1
Part Number
2PGXF
Description
SRV,SW,DPM
Quantity
1
Part Number
384TX
Description
SRV,DRVR,IHID,JEDI
Quantity
1
Part Number
47J28
Description
SRV,DRVR,INTEL VGA,JEDI
Quantity
1
Part Number
51T85
Description
SRV,APPX,THUNDERBOLT,CTL,JEDI
Quantity
1
Part Number
57154
Description
Service Charge,Software, Windows 98,Fully Integrated System Test
Quantity
1
Part Number
6CVXH
Description
SRV,SW,EXCAL,WIN-CMPNT
Quantity
1
Part Number
6KVPR
Description
SRV,DRVR,THUNDERBOLT,CTL,JEDI
Quantity
1
Part Number
6PM2R
Description
SRV,DRVR,DPTF,JEDI
Quantity
1
Part Number
78RGN
Description
SRV,DRVR,AUD,RLTK,JEDI
Quantity
1
Part Number
7NDFW
Description
SRV,OS,WIN10,DCNTD,STDBY
Quantity
1
Part Number
8JGDK
Description
SRV,SW,APP,SMARTBYTE
Quantity
1
Part Number
91W9J
Description
INFO,RYLTY,RIVET,SMARTBYTE,7K
Quantity
1
Part Number
9PX5F
Description
SRV,DRVR,FPR,GOODIX,JEDI
Quantity
1
Part Number
HKN4R
Description
SRV,APPX,IRST,JEDI
Quantity
1
Part Number
J61P6
Description
SRV,DRVR,RLTK,USB,ENET,JEDI
Quantity
1
Part Number
JKJW7
Description
SRV,DRVR,WAVES-MAXX,JEDI
Quantity
1
Part Number
KKHT4
Description
SRV,DRVR,SENSOR HUB,JEDI
Quantity
1
Part Number
M3C3H
Description
INFO,RYLTY,WAVES-MAXX,AUD,PRO
Quantity
1
Part Number
M8G9G
Description
SRV,APPX,INTEL VGA,JEDI
Quantity
1
Part Number
THXM8
Description
SRV,RGSTRY KEY,JEDI 15/17
Quantity
1
Part Number
TM0N4
Description
SRV,DRVR,IRST,JEDI
Quantity
1
Part Number
WDM00
Description
INFO,RYLTY,FORTEMEDIA,TRCK
Quantity
1
Part Number
WXM2C
Description
SRV,BIOS RECOVERY 2
Quantity
1
031K7 : MOD,DIMM,16GB,2X8G,2667,N-ECC Part Number
HYXPX
Description
DIMM,8GB,2666,1RX8,8G,DDR4,S
Quantity
2
Can someone please identify the power port part number from the above?
submitted by alexiskurien to Dell [link] [comments]

2024.06.04 13:21 Few_Actuary9239 This is wrong AGAIN

This is wrong AGAIN submitted by Few_Actuary9239 to SEGAGENESIS [link] [comments]

2024.06.03 21:32 Lunita_good-95 Los malpensados 7n7

Wenaas tengo 15 y tan proto vivo en un mundo así qwq, como ya sabrán, los malpensados son personas que asocian palabras o cosas con partes intimas u otra cosa ofensiva como groserías, una experiencia que tuve con eso :D digo "una" porque no se si alcance xd
......................Videos...........................................
yo me la paso aveces viendo videos en Facebook, y como todo video no podía faltar el de los memes xd 😏 así que me vi uno que me llamo la atención, era un chat meme, ya saben, esos que el meme son dos personas en un chat hablando de cualquier estupidez que sea chistosa para el publico xd, weno, yo me metí en uno de esos :)
Lector: algo va a pasar 😏
Silencio que no termino! >:v ok, como decía: me puse a ver el video, se trataba de que una chica le hacia preguntas algo raras a un chico por WhatsApp (dijo raras porque en ese entonces no sabia que eran otro tipos de preguntas 😆) el chat meme empezó normal, todo parecía estar bien hasta que...
Chica: "oye, te puedo hacer unas preguntas calientes? 🥵"
Yo: *sin entender la pregunta* eh?
Osea, no sabia porque eso 😅 le hacia pregunta tras pregunta y yo no entendía ni una 😅 yo era el chico del chat meme porque el chico tampoco entendía ni una sola pregunta 😅 me tuve que meter en los comentarios para ver que era, y cuando vi...
Yo: *sorprendida y algo asqueada* es enserio? 🤢
Las preguntas eran subidas de tono! osea, quien hace eso? solo un pervertido claro 😑
Lector: y como supiste que eran subidas de tono? algo anda mal🤨
Un amigo me dijo 😅 le mostré el video y le pregunte que eran esas preguntas y solo me dijo que eran subidas de tono y nada mas, no me quiso decir mas nada, tengo 15 y según el mundo de hoy en día se suponía que tenia que saber el significado de todas esas preguntas 🙄 eso cae mal >:v ademas, ni quiero saber que significan esa preguntas 😒
.................compañeros de clase........................
Recuerdo que antes de Semana Santa, mis amigas querían jugar un juego nuevo con mis compañeros en el liceo 🤔 , se llamaba "el juego del malpensado" el juego consiste en poner palabras incompletas y dejar que el resto las completaran, las palabras salían tipo como: cu_o, s_xo, entre otras
Lector: AHI DICE CU-*te lanzo un zapato*
Ni se te ocurra decirlo (╬▔皿▔)╯*suspiro* weno, como decía, era esas entre otras, ellas lo sacaron de un video y las curiosas quisieron hacerlo ಠ_ಠ y la idea principal del juego era que lo malpensaran 😑 y si se lo preguntan, si, toditos lo malpensaron 😶 cosa que no es sorpresa 😅 al final me dieron el papel a mi, yo como no soy malpensada respondí todo bien! y me felicitaron por no tener la mente sucia 😊 al menos gane ya que nunca gano nada 😅 así que todo bien :)
..................~My Pibo 🤙🤍..~..........................
Yo tengo a un amigo, muy pana mio, hasta parecemos hermanos XD nos decimos "pibo" o "piba", y si se lo preguntan, tal como lo puse así esta su apodo en mi Facebook 😁 el punto es que el es muy pero MUY malpensado 😶 pero no tanto eso, si no también que es MUY atrevido 😐 pero así lo quiero yo 😉😅 un día el me estaba contando como se trataba con su novia, como tenia curiosidad quería saber más, pero el me dijo:
Pibo: esta muy pequeña para eso querida, todavía no puedes saber de esto
Y no me dijo :v casi siempre es así, cuando es de un tema así o me dice eso o me lo esquiva, y yo dije entre mi: "¿tanto así?" Dios mio pero que mente tan cochina tiene la gente de hoy en día 😅🤢 pero weno, que se le hace :) total? xd
Lector: mejor que te quedes así 😃
Jeje si... pero weno, hasta aquí mi relato de hoy (al final si alcanzo xd), espero que hayan disfrutado estas anécdotas 💜 nos vemos en un próximo encuentro nwn bye bye 💜👋
submitted by Lunita_good-95 to u/Lunita_good-95 [link] [comments]

2024.06.03 18:21 Gloomy-Rutabaga5914 [FNV] Quarry near Sloan freezes my game

So, I don't know what can cause this. I modded my game pretty much, and it ONLY happens near that location.
I'll list you my mods Arsenal Weapon Overhaul - AR15 Family - Main File
Asurah Reanimation Pack - Supermutant Attack9 hotfix for 0.2.1
Asurah Reanimation Pack 0.2.3.2
Asurah Reanimation Pack main
Asurah AR sound fix
B42 Optics
B42 Optics - ESPless - Supplementary Weapons Pack Patch
BeezaLoadScreens
Bloodbath - 1K
BodySlide and Outfit Studio (for Skyrim SE, but works)
Bouncing Natural Breasts - BNB_Armor (dont't ask)
CBBE conversions for FNV - CBBE Cowgirl Raider (dont't ask)
CBBE conversions for FNV - Combat Uniform
CBBE conversions for FNV - Jeans Outfit v2.0
Colt_M16A2_v_1-1
Cowgirl Raider (DT 14) V 2_4 (dont't ask)
Depth of Field Fix
Fallout NV Cheat Terminal Redux - Version 1.87
Wasteland Sex Module version (dont't ask)
FNV Sexual Innuendo NPCs plugin version 007-36659-007
Hit - VATS Restored
Improved Console
ISControl Enabler and Ironsights adjuster (now ESPless) - ISControl
JIP LN NVSE Plugin
JohnnyGuitar NVSE
kNVSE Animation Plugin - kNVSE
LR-300
Mac - M16A2 AWO A15 and Heffy's ARs Animation Set - Arsenal Weapon Overhaul AR15 Family Patch
New Vegas Script Extender (xNVSE)
New Vegas Stutter Remover - NVSR_4-1-36
NMC New Vegas Patch for ALL Sized packs
NMC's Pre Generated LOD Washed out Wasteland Updated
NMCs Textures NV LARGE Pack all 3 parts
NMCs_Texture_Pack_For_New_Vegas - Naval Chair Fix
NMCs_Texture_Pack_For_New_Vegas - Water Tower Clark County Fix
NV Compatibility Skeleton - NVCS Installer
NVAC - New Vegas Anti Crash
Outfit Replacer T6 - CBBE
ShowOff xNVSE
Stewie Tweaks
T6M Combat Uniform v1_1_1_Full
T6M Jeans Outfit v1_0
T6M Jeans Outfit v1_0_1 Fix Patch
MCM
MCM BugFix 2
Type CBBE - Caliente's Beautiful Bodies Enhancer -CBBE- - Type CBBE - Main, and all additional files for it
TYPE4 - Body and Armors - T4 - BnB and Main
UIO - User Interface Organizer
NMCs_Texture_Pack_For_New_Vegas - 16-9 Ratio Main screen for NMCs Texture Pack (turned off due to redundant mods)
NMC's Pre-Generated Original LOD Updated (turned off due to redundant mods)
I don't know which mod can cause game freeze, and because of that I have to reboot my PC
And my character's textures are a bit bugged, I mean in some places skin is brighter which is weird, and underwear (I mean only panties are underwear) are bugged to, they look like low quality texture put on character model.
Thanks for help in advance and I'm sorry for my english!!!
submitted by Gloomy-Rutabaga5914 to FalloutMods [link] [comments]

2024.06.03 16:33 Shamelessbest First time Peg-E has been kind to me 🎉

First time Peg-E has been kind to me 🎉 submitted by Shamelessbest to monopolygo_fairtrade [link] [comments]

2024.06.03 15:35 Moist_Tie_8404 McGriddle

McGriddle submitted by Moist_Tie_8404 to joeyy [link] [comments]

2024.06.03 15:34 MightBeneficial3302 NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
​
https://preview.redd.it/wzmvzi8e0d4d1.png?width=300&format=png&auto=webp&s=b2953a92fcdfcc9956172ba3e2ad55804d79eac9
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release. The Company’s full set of consolidated financial statements for the three months ended March 31, 2024, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca.
Key Business Highlights
On March 1, 2024, the Company commenced the setup of in-house laboratories and offices to bolster its research and development capabilities, subsequent to entering into lease and construction agreements. Completion of these initiatives is anticipated by the end of June 2024.
On March 22, 2024, the Company completed the acceleration of 12,682,340 warrants issued pursuant to a private placement of units that closed on June 15, 2022. Following the acceleration event, the Company received gross proceeds of US$2.92 million (approximately C$4.0 million) from the exercise of 10,423,629 common share purchase warrants, which represented accelerated and non-accelerated warrants of which 9,684,993 warrants were exercised at a price of C$0.38, 556,818 warrants were exercised at a price of C$0.34, and 181,818 warrants were exercised at a price of C$0.48. The Company exercised its right to accelerate the expiry date of certain warrants to thirty days upon the Company’s common shares exceeded C$0.475 for ten consecutive trading days on the TSX Venture Exchange (“TSXV”). “We appreciate the confidence of the investors who exercise their warrants, and the ongoing support of NurExone’s journey,” stated Eran Ovadya, NurExone Chief Financial Officer.
On April 1, 2024, the Company entered into a Contract Research Organization services agreement with Vivox Ltd. for animal experiments as part of the preclinical testing phase for the submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (the “FDA”). This is aimed at assessing the safety and efficacy of the ExoPTEN drug before proceeding to clinical trials involving human subjects, which are anticipated to commence in 2025. This engagement followed the completion of a Pre-IND meeting with the FDA regarding the manufacturing, preclinical, and clinical development plan of ExoPTEN, NurExone’s inaugural ExoTherapy product, and the subsequent receipt of a written response from the FDA.
On April 25, 2024, NurExone successfully secured approval for listing on the OTCQB Venture Market, marking a significant milestone in the Company's growth and visibility within the financial community, including in the USA. In addition, the Company achieved Depository Trust Company eligibility, which enhances the efficiency and cost-effectiveness of trading NurExone shares, facilitating better liquidity and broader access for investors.
Growth Outlook for 2024
According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is committed to pioneering transformations in the field of regenerative medicine with new, minimally invasive therapies and we are moving along the regulatory path towards human trials for our first product, ExoPTEN. Our focus remains on enhancing our ExoTherapy platform for the production of nanodrugs, expanding our intellectual property, and forging strategic collaborations. Towards this end, we have recently engaged Dr. Ram Petter, Vice President and head of Bio Strategy at Teva Pharmaceutical, to support our efforts in collaborating with biopharma companies.”
First Quarter Fiscal 2024 Financial Results
  • Research and development expenses were US$0.22 million in the first quarter of 2024, compared to US$0.37 million in the same quarter in 2023. The decrease was primarily due to the receipt of a governmental grant of US$0.02 and reductions in stock-based compensation of US$0.08, subcontractor and materials expenses of US$0.05.
  • General and administrative expenses were US$0.70 million in the first quarter of 2024, compared to US$0.35 million in the same period in 2023. The increase was primarily due to costs related to public and investor relations services.
  • Finance expenses were US$0.01 million in the first quarter of 2024, compared to finance income of US$0.01 million in the same period in 2023, driven by income from bank interest.
  • Net loss was US$0.92 million in the first quarter of 2024, compared to a net loss of US$0.70 million in the first quarter of 2023.
As of March 31, 2024, the Company had cash and cash equivalents of US$3.25 million (December 31, 2023 - US$0.54 million) and working capital of US$3.31 million (December 31, 2023 - US$0.07 million). The increase in cash was primarily due to the completion of a private placement in January 2024 for gross proceeds of approximately US$1.49 million and the exercise of warrants in March 2024 for gross proceeds of approximately US$2.92 million.
The Company had an accumulated deficit of US$14.98 million as of March 31, 2024, (December 31, 2023 - US$14.06 million).
Eran Ovadya, NurExone’s Chief Financial Officer, added: “The Company maintains a strong cash position, ensuring sufficient funding until year-end. With strategic oversight, we navigate our business plan amidst ongoing activities, positioning ourselves for sustained growth and continued success.”
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.
For additional information, please visit www.nurexone.com or follow NurExone onLinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com
Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com
Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu
submitted by MightBeneficial3302 to WallStreetbetsELITE [link] [comments]

2024.06.03 15:34 MightBeneficial3302 NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
​
https://preview.redd.it/70y3ywm20d4d1.png?width=300&format=png&auto=webp&s=9c95e7723a815d454a0b6b31c1d7c65ec70abe47
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release. The Company’s full set of consolidated financial statements for the three months ended March 31, 2024, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca.
Key Business Highlights
On March 1, 2024, the Company commenced the setup of in-house laboratories and offices to bolster its research and development capabilities, subsequent to entering into lease and construction agreements. Completion of these initiatives is anticipated by the end of June 2024.
On March 22, 2024, the Company completed the acceleration of 12,682,340 warrants issued pursuant to a private placement of units that closed on June 15, 2022. Following the acceleration event, the Company received gross proceeds of US$2.92 million (approximately C$4.0 million) from the exercise of 10,423,629 common share purchase warrants, which represented accelerated and non-accelerated warrants of which 9,684,993 warrants were exercised at a price of C$0.38, 556,818 warrants were exercised at a price of C$0.34, and 181,818 warrants were exercised at a price of C$0.48. The Company exercised its right to accelerate the expiry date of certain warrants to thirty days upon the Company’s common shares exceeded C$0.475 for ten consecutive trading days on the TSX Venture Exchange (“TSXV”). “We appreciate the confidence of the investors who exercise their warrants, and the ongoing support of NurExone’s journey,” stated Eran Ovadya, NurExone Chief Financial Officer.
On April 1, 2024, the Company entered into a Contract Research Organization services agreement with Vivox Ltd. for animal experiments as part of the preclinical testing phase for the submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (the “FDA”). This is aimed at assessing the safety and efficacy of the ExoPTEN drug before proceeding to clinical trials involving human subjects, which are anticipated to commence in 2025. This engagement followed the completion of a Pre-IND meeting with the FDA regarding the manufacturing, preclinical, and clinical development plan of ExoPTEN, NurExone’s inaugural ExoTherapy product, and the subsequent receipt of a written response from the FDA.
On April 25, 2024, NurExone successfully secured approval for listing on the OTCQB Venture Market, marking a significant milestone in the Company's growth and visibility within the financial community, including in the USA. In addition, the Company achieved Depository Trust Company eligibility, which enhances the efficiency and cost-effectiveness of trading NurExone shares, facilitating better liquidity and broader access for investors.
Growth Outlook for 2024
According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is committed to pioneering transformations in the field of regenerative medicine with new, minimally invasive therapies and we are moving along the regulatory path towards human trials for our first product, ExoPTEN. Our focus remains on enhancing our ExoTherapy platform for the production of nanodrugs, expanding our intellectual property, and forging strategic collaborations. Towards this end, we have recently engaged Dr. Ram Petter, Vice President and head of Bio Strategy at Teva Pharmaceutical, to support our efforts in collaborating with biopharma companies.”
First Quarter Fiscal 2024 Financial Results
  • Research and development expenses were US$0.22 million in the first quarter of 2024, compared to US$0.37 million in the same quarter in 2023. The decrease was primarily due to the receipt of a governmental grant of US$0.02 and reductions in stock-based compensation of US$0.08, subcontractor and materials expenses of US$0.05.
  • General and administrative expenses were US$0.70 million in the first quarter of 2024, compared to US$0.35 million in the same period in 2023. The increase was primarily due to costs related to public and investor relations services.
  • Finance expenses were US$0.01 million in the first quarter of 2024, compared to finance income of US$0.01 million in the same period in 2023, driven by income from bank interest.
  • Net loss was US$0.92 million in the first quarter of 2024, compared to a net loss of US$0.70 million in the first quarter of 2023.
As of March 31, 2024, the Company had cash and cash equivalents of US$3.25 million (December 31, 2023 - US$0.54 million) and working capital of US$3.31 million (December 31, 2023 - US$0.07 million). The increase in cash was primarily due to the completion of a private placement in January 2024 for gross proceeds of approximately US$1.49 million and the exercise of warrants in March 2024 for gross proceeds of approximately US$2.92 million.
The Company had an accumulated deficit of US$14.98 million as of March 31, 2024, (December 31, 2023 - US$14.06 million).
Eran Ovadya, NurExone’s Chief Financial Officer, added: “The Company maintains a strong cash position, ensuring sufficient funding until year-end. With strategic oversight, we navigate our business plan amidst ongoing activities, positioning ourselves for sustained growth and continued success.”
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.
For additional information, please visit www.nurexone.com or follow NurExone onLinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com
Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com
Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu
submitted by MightBeneficial3302 to CanadianStockExchange [link] [comments]

2024.06.02 11:15 Lonely-Preference-10 Stuck on this part for a long time please help me

Stuck on this part for a long time please help me submitted by Lonely-Preference-10 to animalWell [link] [comments]

2024.06.02 06:20 MrHomelessUploadMore Found away into the chimera boss arena while exploring the buildings around dogtown

Found away into the chimera boss arena while exploring the buildings around dogtown submitted by MrHomelessUploadMore to cyberpunkgame [link] [comments]

2024.06.02 05:45 smash504 Ground textures (pebbles?) disappearing at a slight distance (video for context below)

https://youtu.be/_v_PN3U_hHA
i am using some texture overhauls and community shaders but im wondering if this has anything to do with my view distance
MODLIST 
 "(Part 1) SSE Engine Fixes for 1.5.39 - 1.5.97", "Male Npc Overhaul - --fomod--USSEP and AI overhaul SSE patch", "1DwemerArmorSE", "1NDArmorSE", "1YsmirArmorSE", "Infantry Armor SE - 1fsse", "Male Dragonic Argonian Textures 4k - 2k (SOS and Vanilla) - 2K SOS", "Female Dragonic Argonian Textures 4k - 2k(CBBE and UNP) - 4k CBBE", "A Quality World Map 9.0.1 - Vivid with Flat Roads", "AI Overhaul for SE Only 1.8.5", "AddItemMenuSE\_114\_SKSE2019", "Address Library for SKSE Plugins - All in one (Special Edition)", "Amazing Follower Tweaks", "Animation Motion Revolution", "Animation Queue Fix", "ArteFakes - Unique Artifacts Replacer - ArteFakes", "Audio Overhaul for Skyrim (4.1.3)", "AutoBody AE - Configurable Randomized Bodies - AutoBody AE 1.5.1", "Autobody AE 1.5.1 - recompiled for SSE 1.5.97", "BM\_Brows\_HPH", "Vanilla Scripting Enhancements - BSA Version", "Base Object Swapper", "BattlemageArmor", "Better Jumping SE", "Better Third Person Selection (AE - SE)", "Bijin NPCs SE 1.2.1", "BodySlide and Outfit Studio", "Bosmer NPCs have antlers - FOMOD Installer", "Brows - TRE Brows - High Poly Head Patch", "Brows - TRE Brows", "CBBE 3BA (3BBB)", "Caliente's Beautiful Bodies Enhancer -CBBE- - CBBE AE-CC Outfits", "CBPC - Physics with Collisions for SSE and VR - CBPC - Fomod installer - MAIN FILE", "Caliente's Beautiful Bodies Enhancer CBBE - v2.0.3", "Cathedral - Water", "Compass Navigation Overhaul", "ConsolePlusPlus", "CoverKhajiits 4K", "Constructible Object Custom Keyword System - Crafting Categories for SkyUI", "Crash Logger", "Creamy Curves - CBBE 3BAv2 Bodyslide Preset", "DIbella's Blessing", "Detection Meter-v1.11", "Dialogue Interface ReShaped", "Dialogue Movement Enabler (Latest version for SE)", "DigitigradeKhajiit\_ArgonianRaptor", "Dynamic Torch Idle Animations - OAR", "Expressive Facegen Morphs SE - EFM SE - Racemenu plugin", "ELFX Fixes", "Elisa face preset", "Enhanced Lights and FX", "Even More Brows HPH", "Expressive Facegen Morphs SE", "Expressive Facial Animation - Female Edition", "Fores New Idles in Skyrim SE - FNIS SE - FNIS Behavior SE 7\_6", "FSMPV - FSMP-Validator - HDT-SMP XML Schema - FSMPV", "Face Discoloration Fix SE (1.5.97)", "Faster HDT-SMP", "Favorite Misc Items", "Follower Trap Safety", "Footprints 1.6.1", "Forget Spell (1.5.97)", "Galactic eyes 4k", "Glorious Doors of Skyrim (GDOS) SE", "HDT-SMP Racemenu Hair or Wigs - Xing - Dint999 - Fuse00 - HHairstyles - KS - HG - SG - NO RING Version - HDT-SMP Hairs and Wigs - FOMOD", "Highly Improved Male Body Overhaul -HIMBO- - HIMBO V5 - Core", "Happy Little Trees - HLT Patch", "High Quality 3D Map - HQ3DMap - Meshes Med-Res", "Happy Little Trees", "High\_Poly\_Head\_v1.4\_(SE)", "High elf mid hi poly", "Hiraya Brows for High Poly Head", "Horse Stamina HUD (1.5.97)", "Brows - Hvergelmir's Aesthetics - Brows 4.1", "Improved Follower Dialogue - Lydia", "Infinite Horse Stamina Out of Combat", "Infinite Magicka Out of Combat", "Infinite Stamina Out of Combat", "Infinity UI", "Insignificant Object Remover", "Iridum Eyes", "JContainers SE", "JK's Skyrim all in one", "KS Hairdos SMP 3BA Collision Bodyslides Low to High ESPFE", "KS Hairdos SMP", "KS Hairdos SSE - Female", "Kalilies Brows", "Keyword Item Distributor", "Kyoe's Bang'n Brows PLUS PLUS v1.0", "Lightened Skyrim", "Lorraine High Poly Racemenu Preset SE", "Lucy - High Poly Racemenu Preset SE", "Lucy - High Poly Racemenu Preset", "MCM Helper SE (1.5.97)", "Magic Sneak Attacks", "Highly Improved Male Body Overhaul -HIMBO- - Main File (FOMOD Installer)", "Sons of Skyrim - Main Files", "Male Npc Overhaul v12 fixed", "Mea -Nord- High-Poly Head Racemenu Face Preset - Mea", "MergeMapper", "MikanEyes v2.5 SE", "Modular SMP Hairstyles", "More Informative Console 1.2", "Mortal Enemies v1.4", "No Grass In Objects - NGIO - Special Edition (1.5.97)", "Nemesis Unlimited Behavior Engine", "No Camera Filters", "Obsidian Weathers - 1.07a", "Open Animation Replacer", "Opulent Retexture 2K", "Oxygen Meter 2 - OxygenMeter2 FOMOD SSE AE640 AE1170", "Paired Animation Improvements", "Papyrus Extender", "PapyrusUtil SE - Scripting Utility Functions", "Precision - Accurate Melee Collisions - Precision", "QuickLoot EE", "RSSE Children Overhaul 1.1.3 with hotfix 1", "RaceMenu High Heels Fixes", "RaceMenu - RaceMenu Special Edition v0-4-14", "Read or Take SKSE", "Recipes 1.1.1", "Recursion Fix", "Remember Lockpick Angle", "Replace Nirnroot Sound with Wind Chimes", "Rich Skyrim Merchants", "SC - KS Hairdos Retextured", "Scripts Carefully Reworked Optimized and Tactfully Enhanced (SCROTE) - Simply Optimized Scripts AIO - SCROTE BSA Version", "Static Mesh Improvement Mod - SMIM - SMIM SE 2-08", "SPID for Footprints", "SSE Display Tweaks", "Savior's Hide Replacer", "ScaleformTranslationPP", "Schlongs of Skyrim SE - Settings Loader", "Schlongs\_of\_Skyrim\_SE - v1.1.4", "Security Overhaul SKSE - Add-ons", "Security Overhaul SKSE - Lock Variations", "Sentinel - An Equipment Overhaul", "Simple Horse SE", "Skin Feature Overlays SE - Freckles Scars Birthmarks Stretch Marks Moles and More for Face and Body RaceMenu Overlays - SkFO SE -Skin Feature Overlays- 4K", "SkyPatcher - SE", "SkyUI\_5\_2\_SE", "Skyland AIO", "Skyrim Landscape and Water Fixes - FOMOD", "Skyrim Priority SE AE (3.4.0)", "Slaughterfish are Extinct", "Sonders Keyword Distribution Resources", "Sound Record Distributor", "Spell Perk Item Distributor", "Super Fast Get Up Animation", "Terre's 4K Fur Textures for CoverKhajiits - Vanilla CBBE UNP BHUNP SoS HIMBO - Terre's Body Fur Textures AIO - 4K", "The Pure CBBE and UNP - 4K or 8K Female Skin Textures - The Pure - CBBE", "The Witcher 3 Eyes", "True Brows SE - Standalone", "True Directional Movement", "TrueHUD", "UIExtensions v1-2-0", "Unofficial Skyrim Special Edition Patch", "Use Or Take SKSE", "User Heels Keyword Distribution", "Vanilla Script MicroOptimizations", "VioLens - A Killmove Mod SE 2.30", "Visual Animated Enchants 2-023 Se Ae version", "Simplicity of Sea - Water Mod with ENB Displacement Textures - Water Mod", "Whose Quest Is It Anyway", "XP32 Maximum Skeleton Special Extended", "1) aMidianBorn Book of Silence SE -- COMPLETE", "powerofthree's Tweaks", "practical\_pirate", "practical\_pirate\_cbbe", "practical\_pirate\_physics", "Auto Parallax", "Community Shaders", "Vanilla HDR", "Water Blending", "Complex Parallax Materials" "tag": "Vortex - ml"
submitted by smash504 to skyrimmods [link] [comments]

2024.06.02 05:44 JesusAmbassador God Always Restores Psalm 85:1-9 Our Daily Bread Video Devotional

God Always Restores Psalm 85:1-9 Our Daily Bread Video Devotional submitted by JesusAmbassador to PrayerTeam_amen [link] [comments]

2024.06.02 05:44 JesusAmbassador God Always Restores Psalm 85:1-9 Our Daily Bread Video Devotional

God Always Restores Psalm 85:1-9 Our Daily Bread Video Devotional submitted by JesusAmbassador to JesusChrist [link] [comments]

2024.06.01 22:40 10tlacuachestururu memes random 🚰

memes random 🚰 submitted by 10tlacuachestururu to memexico [link] [comments]

2024.06.01 11:48 Vicious_Antelope 50 Vintage Cinematic Omnisphere 2 Patches

50 Vintage Cinematic Omnisphere 2 Patches
VHS Times Vol.1 contains 50 Omnisphere 2 patches inspired by cinematic music of the eighties, and more specific from this time’s sound perspective in the sci-fi themed music. With it retrofuturistic sound this soundbank fits for vintage cinematic music as well as some experimental cinematic based synthwave productions.Here you can find 37 polysynths and 13 synth pads. With the MW you could add a touch of pitch modulation that brings in mind that distinctive vintage sonic characteristic of VHS movies music.Bass dominant synths, soft plucky dreaming sounds, analog sci-fi pads, calm interstellar atmospheres, moving synths, interesting weird keys are some of the characteristics of the included synth presets.
Grab it at: https://www.viciousantelope.com/.../vhs-time-vol-1...
Presets walkthrough video: https://youtu.be/LcHPtSxlH0A?si=Wf__AdafPaPAMk5E
#synth #synthesizer #music #musicproducer #musicproducers #musicproduction #musician #musicianlife #ableton #abletonlive #flstudio #cubase #protools #studio #synth #inspiration #sound #sounddesign #producer #bedroomproducer #composer #cinematicmusic #ambientmusic #electronicmusic #synthwave #instrumental #songwriter #viciousantelope #omnisphere
Omnisphere 2 Patches
submitted by Vicious_Antelope to Vicious_Antelope [link] [comments]

2024.05.31 08:13 Void_49 2010…

2010…
Yeah…remember that year?
I just..can’t put my finger on it, but 2010 was such a nostalgic year for me, because I was born in 2010
And it was great….no skibidi, no Ohio Memes…Just…Classics
submitted by Void_49 to GenAlpha [link] [comments]

2024.05.30 00:45 chloestevens160 My Green Day merch collection!

My Green Day merch collection!
Here is all of my GD merch!!! I’ve been dying to share my collection!!! Just got Kerplunk on cd today so today felt like the day. Not pictured is a few more GD stickers I have on my car and some stickers on my water bottle as well as a GD keychain on my car keys :) not trying to brag at all- super grateful for everything I have
submitted by chloestevens160 to greenday [link] [comments]

http://activeproperty.pl/